Priorities for developing respiratory syncytial virus vaccines in different target populations

Drysdale SB., Barr RS., Rollier CS., Green CA., Pollard AJ., Sande CJ.

About 38 candidate vaccines and monoclonal antibodies are in clinical development for treating respiratory syncytial virus in different populations.

DOI

10.1126/scitranslmed.aax2466

Type

Journal

Science Translational Medicine

Publisher

American Association for the Advancement of Science (AAAS)

Publication Date

18/03/2020

Volume

12

Permalink Original publication